Skip to main content
PGNY logo

PGNY · Progyny, Inc.

Track PGNY — free
$36.86 +0.70 (+1.94%)
Market Cap
$2.66B
Shares
73.65M
Volume · Nov 18 913.51K Avg daily vol (3M) 1.1M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$36.16 Open$36.67 Day$35.63–37.21 52W close$16.30–37.15 Avg vol 30d1.0M Short int4.8M · 6.5% of shares · 6.3d Short vol51% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 9% as gross profit jumps 15%

Progyny said revenue increased by $27.9 million, or 9%, and gross profit increased by $10.9 million, or 15%, for the three months ended September 30, 2026 compared with September 30, 2025.

Revenue $341.25M ▲ 8.9% Net income $26.25M ▲ 89.4% Diluted EPS $0.32 ▲ 113.3%
Read from the MD&A section
3 source passages
Progyny is a global leader in women’s health and family building solutions. Revenue increased by $27.9 million, or 9%, for the three months ended September 30, 2026 compared to the three months ended September 30, 2025. Gross profit increased by $10.9 million, or 15%, for the three months ended September 30, 2026 compared to the three months ended September 30, 2025. Open the document at this passage
Nov 4
Earnings call
Raises 2026 guidance after strong third-quarter performance

Progyny reported record third-quarter revenue and profitability, a selling season yielding record 1.3 million new covered lives and over 85 clients, near 100% retention, and raised full-year 2026 guidance.

5 source passages
I'm pleased to report that Progeny had a strong quarter, resulting in record revenue and profitability for the third quarter We're exceptionally pleased with our results this selling season, which yielded a record 1.3 million new covered lives and over 85 new clients. We saw this favorable activity continue over the balance of the season, leading to yet another year of near 100% retention of the existing base. our financial outlook for both the fourth quarter and full year 2026 we're pleased to be in a position to raise the midpoint of our full-year guidance Open the document at this passage
Nov 4
Current report 8-K
Record third-quarter revenue supports raised full-year guidance

Progyny reported record third-quarter revenue of $341.3 million, up 8.9%, net income of $26.3 million and Adjusted EBITDA of $58.4 million. It raised full-year 2026 revenue guidance to $1.365 billion to $1.385 billion.

Financial results, Regulation FD disclosure Read from the first part of this long document
5 source passages
Progyny, Inc. Announces Third Quarter 2026 Results Revenue was $341.3 million, an 8.9% increase as compared to the $313.3 million reported in the third quarter of 2025, due to an increase in the number of clients and covered lives. Net income was $26.3 million, or $0.32 income per diluted share, as compared to the $13.9 million, or $0.15 income per diluted share, reported in the third quarter of 2025. Adjusted EBITDA was $58.4 million, an increase of 6.3% as compared to the $55.0 million reported in the third quarter of 2025, as the higher gross profit was partially offset by planned investments to expand the features and functionality of our platform. Revenue is projected to be $1.365 billion to $1.385 billion, reflecting growth of 5.9% to 7.5%; excluding the $48.5 million of revenue in 2025 from the large client who was under a transition agreement in the first half of 2025, revenue is expected to increase by 10.1% to 11.7% Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.34B
Trailing 12 months
Net income (TTM)
$91.02M
Trailing 12 months
Revenue growth YoY
+8.9%
Year over year
Operating margin
9.4%
Trailing 12 months
P / E (TTM)
33.2
Trailing earnings · reciprocal yield 3.0%
FCF yield
6.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-10.0%
Year over year · fewer shares
Price change (1Y)
+39.9%
Trailing year
Short interest
6.5%
Latest settlement · 6.3 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26

TL;DR. Progyny delivered record quarterly revenue, gross profit, and adjusted EBITDA with 180 bps of gross margin expansion while reiterating full-year 2026 revenue guidance of $1.36–$1.385 billion and Q3 guidance that reflects a slightly more pronounced summer seasonality. The company repurchased an additional 2 million shares under a new $200 million program and reported strong selling-season momentum with early commitments pacing meaningfully ahead of last year.

Bullish
  • + Reported record quarterly revenue of $350.5M with 5.3% reported growth (11% ex-large former client) and record adjusted EBITDA of $62.1M.
  • + Gross margin expanded 180 basis points year-over-year to 25.5%, reflecting care-management efficiencies and lower stock-based compensation.
  • + Selling-season momentum accelerated, with early commitments pacing meaningfully ahead of last year and retention risk largely removed earlier than usual.
  • + Reiterated full-year 2026 revenue guidance of $1.360–$1.385B (9.7–11.7% ex-large former client) and adjusted EBITDA of $233–$240M.
Bearish
  • − Q3 guidance of $335–$345M revenue and $56–$59M adjusted EBITDA reflects slightly more pronounced summer seasonality than in prior years.
  • − CapEx rose to $6.2M in Q2, a $1M increase year-over-year, as the company continues a multi-year platform investment cycle.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +45%
above
Price vs 50-day avg +24%
above
RSI (14) 73
overbought
MACD trend Positive
52-week position 95%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +27%
trailing
6-month return +41%
trailing
YTD return +41%
this year
Relative strength +45%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $29 › 200d $25 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +38 funds added
Insider flow Distributing
Net -$311.9K over 90 days · 100% sells
Short interest Falling
6.46% of shares out · ▼ -1.9% MoM · 6.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
306 holders — mid 3-yr range
Squeeze score 71
high risk · 0–100
Fundamentals
Excellent
Revenue growth +10%
Y/Y
Gross margin 24%
expanding
EPS growth +14%
Y/Y
Free cash flow $191.8M
Valuation P/E 33.2
rich
Buyback $51.0M
remaining
Quant / Vol
risk profile
Very High
Volatility 50%
annualized · 1-yr
Max drawdown −43%
past year
ATR 3.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 7 of last 8
Latest guidance · from the 8-K filed Nov 4, 2026
Full Year 2026
Revenue Raised $1.37B – $1.39B
Aug 6, 2026 $1.36B – $1.39B changed to Nov 4, 2026 $1.37B – $1.39B
prior FY $1.29B midpoint +6.7% Y/Y
Net Income Raised $107M – $110.6M
May 7, 2026 $103.7M – $112.3M changed to Nov 4, 2026 $107M – $110.6M
Fourth Quarter of 2026
Revenue $344.7M – $364.7M
prior qtr $341.25M midpoint +3.9% QoQ
Net income per diluted share GAAP $0.36 – $0.41
prior qtr $0.32 midpoint +20.3% QoQ
Net income $28.5M – $32.1M
Previous outlook earlier release · from the Earnings Call filed Aug 6, 2026

Still-open targets the latest release did not restate under the same label.

Earnings per diluted share · full year 2026 $1.26 – $1.32
Adjusted EPS · full year 2026 $2.04 – $2.10
Revenue · third quarter $335M – $345M
Net income · third quarter $24.5M – $26.7M
Adjusted EBITDA · third quarter $56M – $59M
Earnings per diluted share · third quarter $0.30 – $0.33
Adjusted EPS · third quarter $0.50 – $0.52
Prior guidance period ended · from the Earnings Call filed May 7, 2026
Revenue · second quarter $342M – $355M
Adjusted EBITDA · second quarter $58M – $62M
Net income · second quarter $25.8M – $28.7M
Earnings per diluted share · second quarter $0.31 – $0.35
Adjusted EPS · second quarter $0.50 – $0.53
Guided vs delivered · last 8 settled
Revenue second quarter
guided $342M – $355M
$350.51M In line
Earnings per diluted share second quarter
guided $0.31 – $0.35
$0.34 In line
Revenue First Quarter of 2026
guided $319M – $332M
$328.5M In line
Net income per diluted share First Quarter of 2026
guided $0.24 – $0.27
$0.29 Beat +13.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+45% Bullish
Price vs 50-day avg
+24% Bullish
RSI (14)
73 Bearish
MACD trend
Positive Bullish
52-week position
95% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $29 › 200d $25 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +38 funds added
Insider flow Distributing
Net -$311.9K over 90 days · 100% sells
Short interest Falling
6.46% of shares out · ▼ -1.9% MoM · 6.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
306 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $16 Now $36 · 95% Range high $37
vs 200-day avg +45% vs 50-day avg +24%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted Earnings Per Diluted Share non-GAAP $1.04 Six Months Ended June 30, 2026 —
Adjusted EBITDA non-GAAP $62.1M Second Quarter 2026 —
GAAP → non-GAAP reconciliation
GAAP Net income 28.05M
+1.62M Depreciation and amortization
+20.48M Stock-based compensation expense
-1.13M Interest and other income, net
+13.09M Provision for income taxes
= Adjusted EBITDA 62.1M
Adjusted EBITDA Margin non-GAAP 17.7% Second Quarter 2026 —
ART Cycles per Unique Female Utilizer 0.51 Three months ended June 30, 2026 —
Assisted Reproductive Treatment (ART) Cycles 32,645 Six Months Ended June 30, 2026 —
Average Members 7,176,000 Six Months Ended June 30, 2026 —
Female Utilization 0.49% 2Q 2026 —
fertility and family building clients 604 As of June 30, 2026 —
Utilization - All Members 0.85% Six Months Ended June 30, 2026 —
Utilization - Female Only 0.71% Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Healthcare Plans — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PGNY
Progyny, Inc.
this stock
$2.66B +40.8% +10.4% 33.2 6.5%
UNH
Unitedhealth Group Inc
$313.53B +6.0% +11.8% 20.0 1.6%
CVS
CVS HEALTH Corp
$104.09B +2.5% +7.8% 9.5 1.4%
ELV
Elevance Health, Inc.
$86.60B +14.3% +12.5% 17.0 2.1%
CI
Cigna Group
$75.20B +3.7% +11.2% 12.6 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
306
% held
104.3%
Net QoQ
-1.7M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
332
View
Short & Settlement
Short Interest Falling
Shares short
4.8M
Days to cover
6.3d
Change
-90.9K sh
View
Short Volume
Short vol %
51%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
23.0K
Value
$658.3K
As of
Oct 21, 2026
View
Off-Exchange
Off-exchange %
34.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$311.9K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Josh Gottheimer
Amount
$1.0K–$15.0K
Traded
Dec 6, 2024
View
Financials
Financials
Revenue (FY)
$1.3B
Net income (FY)
$58.5M
EPS diluted
$0.65
View
Buybacks
Authorized
$200.0M
Remaining
$51.0M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
23

Progyny said revenue increased by $27.9 million, or 9%, and gross profit increased by $10.9 million, or 15%, for the three months ended September 30, 2026 compared with September 30, 2025.

View
Proposed Sales
Value
$28.2K
Shares
774
Filed
Nov 12, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
Progyny, Inc. Announces Third Qua…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
PGNY -0.9% +27.1% +41.5% +23.9% +40.8%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +3.0% +32.7% +44.9% +27.3% +33.7%

Capital returns

Buyback program · as of Nov 4, 2026
Authorized
$200.00M
Spent (derived)
$149.00M
Remaining
$51.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1551306 CUSIP 74340E103 13F (30d) 310 filings 287 filers Visit website Investor relations